Breaking News, Collaborations & Alliances

Conduit Pharma Acquires Exclusive Rights to AstraZeneca’s Promising Drug Candidates

Plans to initiate Phase II clinical trials for AZD1656 and AZD5658 in autoimmune disorders in 2024.

Author Image

By: Charlie Sternberg

Associate Editor

Conduit Pharmaceuticals Inc., which recently opened a new lab space in the UK, has entered into an agreement with AstraZeneca to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators, and AZD5904, a myeloperoxidase inhibitor (MPO). All three drug candidates have shown promise in early-stage clinical trials.   Conduit plans to initiate Phase II clinical trials for AZD1656 and AZD5658 in autoimmune disorders in 2024. The company has also secured exclusive ri...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters